These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 28649891)

  • 21. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
    Sikaria S; Aldoss I; Akhtari M
    Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy in adult acute leukemia.
    Blum S; Martins F; Lübbert M
    Leuk Res; 2017 Sep; 60():63-73. PubMed ID: 28756350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
    Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
    Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody and Cellular-Based Therapies for Pediatric Acute Lymphoblastic Leukemia: Mechanisms and Prospects.
    Li W; Zhang Y; Kankala RK; Zou L; Chen Z
    Pharmacology; 2022; 107(7-8):368-375. PubMed ID: 35390793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma.
    DuVall AS; Wesevich A; Larson RA
    Curr Hematol Malig Rep; 2023 Dec; 18(6):217-225. PubMed ID: 37490229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia.
    Dinner S; Lee D; Liedtke M
    Leuk Lymphoma; 2014 Aug; 55(8):1715-24. PubMed ID: 24251864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab.
    Wilke AC; Gökbuget N
    Expert Opin Drug Saf; 2017 Oct; 16(10):1191-1202. PubMed ID: 28825327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cutting to the Front of the Line: Immunotherapy for Childhood Acute Lymphoblastic Leukemia.
    McNeer JL; Rau RE; Gupta S; Maude SL; O'Brien MM
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-12. PubMed ID: 32320280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia.
    Silverman LB
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):259-264. PubMed ID: 29222264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapies on the horizon for childhood acute lymphoblastic leukemia.
    Carroll WL; Hunger SP
    Curr Opin Pediatr; 2016 Feb; 28(1):12-8. PubMed ID: 26576011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
    Farhadfar N; Litzow MR
    Leuk Res; 2016 Oct; 49():13-21. PubMed ID: 27521873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy in pediatric acute lymphoblastic leukemia.
    Inaba H; Pui CH
    Cancer Metastasis Rev; 2019 Dec; 38(4):595-610. PubMed ID: 31811553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Therapies in Acute Lymphoblastic Leukemia.
    Phelan KW; Advani AS
    Curr Hematol Malig Rep; 2018 Aug; 13(4):289-299. PubMed ID: 30078158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development.
    Thomas X
    Expert Opin Investig Drugs; 2023 Jan; 32(1):37-52. PubMed ID: 36541671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment.
    Thomas X; Heiblig M
    Expert Opin Drug Discov; 2016 Nov; 11(11):1061-1070. PubMed ID: 27548716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.
    Hoelzer D
    Curr Opin Oncol; 2013 Nov; 25(6):701-6. PubMed ID: 24097105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia.
    Tvito A; Rowe JM
    Expert Opin Biol Ther; 2017 Dec; 17(12):1557-1564. PubMed ID: 29092647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome.
    Marini BL; Sun Y; Burke PW; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Jan; 24(1):67-73. PubMed ID: 27799606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relapsed/Refractory T- Acute Lymphoblastic Leukemia - Current Options and Future Directions.
    Jeha S
    Indian J Pediatr; 2024 Feb; 91(2):168-175. PubMed ID: 37642889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.